Loading company
Celldex Therapeutics, Inc.
CLDX · Nasdaq · ·
Next earnings: November 9, 2026
$31.62+0.3%Sep 29 close
- 1M
- -19.2%
- 6M
- +7.3%
- 1Y
- +22.2%
- 5Y
- -42.5%
CLDX · Nasdaq · ·
Next earnings: November 9, 2026
$31.62+0.3%Sep 29 close
Celldex Therapeutics, Inc. is scheduled to report next on November 9, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $22K | $730K | -96.99% |
| Profit | -$73.5M | -$56.6M | -29.86% |
| Profit per share | -$0.94 | -$0.85 | -10.59% |
| Free Cash Flow | -$60.6M | -$44.7M | -35.45% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“We are leaders in mast cell science with a pipeline of programs that have the potential to dramatically shift treatment paradigms for patients,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Celldex is pioneering new horizons in immunology to deliver life-changing therapies. We are relentless in our pursuit of novel antibody-based treatments that engage the human immune system and directly affect critical pathways to improve the lives of patients with allergic, inflammatory and autoimmune disorders. Visit www.celldex.com.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Celldex Therapeutics, Inc.’s Item 2.02 8-K filed August 6, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Celldex Therapeutics, Inc. has no earnings call transcript available.